|
注册号: Registration number: |
ChiCTR2500096644 |
|
最近更新日期: Date of Last Refreshed on: |
2025-01-27 14:52:50 |
|
注册时间: Date of Registration: |
2025-01-27 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
乳腺癌术后患者上肢淋巴水肿全程管理干预模式的研究 |
|
Public title: |
Study on intervention mode of upper limb lymphedema management after breast cancer surgery |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
乳腺癌术后患者上肢淋巴水肿全程管理干预模式的研究 |
|
Scientific title: |
Study on intervention mode of upper limb lymphedema management after breast cancer surgery |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘艳飞 |
研究负责人: |
刘均娥 |
|
Applicant: |
Yanfei Liu |
Study leader: |
Liu Jun’e |
|
申请注册联系人电话: Applicant telephone: |
+86 188 1082 9490 |
研究负责人电话:
Study leader's |
+86 185 0013 6128 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
851122725@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
liujune66@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河南省郑州市高新区科学大道101号 |
研究负责人通讯地址: |
北京市丰台区右安门外西头条10号首都医科大学 |
|
Applicant address: |
No.101 Science Avenue, High-tech Zone, Zhengzhou, Henan |
Study leader's address: |
Capital Medical University, No. 10, Xitou Tiao, You'anmen Outer, Fengtai District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
郑州大学护理与健康学院 |
||
|
Applicant's institution: |
School of Nursing and Health, Zhengzhou University |
||
|
研究负责人所在单位: |
首都医科大学 |
||
|
Affiliation of the Leader: |
Capital Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
Z2019SY022 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2019-04-23 00:00:00 | ||
|
伦理委员会联系人: |
刘芳 |
||
|
Contact Name of the ethic committee: |
Liu Fang |
||
|
伦理委员会联系地址: |
北京市丰台区右安门外西头条10号首都医科大学 |
||
|
Contact Address of the ethic committee: |
Capital Medical University, No. 10, Xitou Tiao, You'anmen Outer, Fengtai District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8391 1736 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
首都医科大学 |
||||||||||||||||||||||
|
Primary sponsor: |
Capital Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市丰台区右安门外西头条10号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 10, Xitou Tiao, You'anmen Outer, Fengtai District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京市自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing Natural Science Foundation |
||||||||||||||||||||||
|
研究疾病: |
乳腺癌淋巴水肿 |
||||||||||||||||||||||
|
Target disease: |
Breast cancer lymphedema |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
评价运动干预对乳腺癌淋巴水肿,健康体适能,心理状况和生活质量的影响等。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effects of exercise intervention on lymphedema, physical fitness, psychological status and quality of life of breast cancer. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
①已复发或转移; ②合并有其它癌症; ③既往患有精神病史及意识障碍; ④患侧上肢有骨折、手术、神经损伤或其他疾病而影响锻炼; ⑤合并其他严重疾病(如严重高血压、心脏病等)不能配合本研究; ⑥既往有精神疾病。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Has recurred or metastasized; 2. Combined with other cancers; 3. Have a history of mental illness and consciousness disorder; 4. There are fractures, surgery, nerve damage or other diseases on the affected side of the upper limb that affect exercise; 5. Combined with other serious diseases (such as severe hypertension, heart disease, etc.) can not cooperate with this study; 6. Previous mental illness. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-09-10 00:00:00至 To 2020-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2019-09-28 00:00:00 至 To 2020-01-03 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,ResMan, http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the study, ResMan, http://www.medresman.org.cn/login.aspxo |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究运用 Epi Data3.1双人录入进行数据统计,运用IBM SPSS Statistics 24.0统计软件进行数据分析 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
In this study, Epi Data 3.1 was used for data statistics and IBM SPSS Statistics 24.0 statistical software was used for data analysis |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |